Answers are grounded in this paper and cite their sources.
Bladder cancer (BCa) is one of the most common malignant tumors of the urinary system and represents an increasingly serious public health problem worldwide. Dysregulated glycolysis is a key feature of metabolic reprogramming in BCa, and aberrant expression of enolase 1 (ENO1) is closely associated with tumor progression. This study aimed to identify novel deubiquitinases that regulate ENO1 ubiquitination and stability in BCa. We found that the deubiquitinating enzyme ubiquitin c-terminal hydrolase L3 (UCHL3) is highly expressed in BCa tissues (TCGA–GTEx and tissue microarray) and positively correlates with ENO1 levels, and that high UCHL3 expression predicts poor prognosis in patients with BCa in the GSE13507 cohort. Functionally, UCHL3 knockdown markedly reduced ENO1 protein levels and impaired glycolysis. Mechanistically, the C-terminal domain of UCHL3 directly interacted with the triose-phosphate isomerase (TIM) barrel domain of ENO1 and stabilized ENO1 by suppressing its ubiquitination. Moreover, UCHL3 knockdown inhibited BCa cell proliferation, migration and glycolysis. Crucially, phenotypic rescue experiments demonstrated that these malignant behaviors driven by UCHL3 were largely dependent on ENO1. Collectively, our findings demonstrate that UCHL3 activates glycolysis by deubiquitinating ENO1, and that its high expression promotes BCa cell proliferation, migration, glycolysis, and tumor growth. These results suggest that targeting UCHL3 may represent a promising therapeutic strategy for BCa.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: